The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance

Cyclin-dependent kinases (CDKs) govern cell-cycle checkpoint transitions necessary for cancer cell proliferation. Recent developments have illustrated nuanced important differences between mono CDK inhibitor (CDKI) treatment and the combination therapies of breast cancers. The CDKIs that are current...

Full description

Bibliographic Details
Main Authors: Mary Abdelmalak, Rajanbir Singh, Mohammed Anwer, Pavel Ivanchenko, Amritdeep Randhawa, Myra Ahmed, Anthony W. Ashton, Yanming Du, Xuanmao Jiao, Richard Pestell
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
abemaciclib
advanced breast cancer
CDK4/6 inhibitor
hormone receptor-positive
palbociclib
ribociclib
Online Access:https://www.mdpi.com/2072-6694/14/21/5388

Internet

https://www.mdpi.com/2072-6694/14/21/5388

Similar Items